Choriocapillaris vascular density and choroidal vascularity index in quiescent macular neovascularization: correlations in conversion to exudative disease or geographic atrophy
Componente | Categoria |
---|---|
Gianluca Scuderi | Componenti strutturati del gruppo di ricerca |
Componente | Qualifica | Struttura | Categoria |
---|---|---|---|
Luigi Fabrizio | Dirigente Medico | UOD Oftalmologia, Università di Roma Sapienza | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
Andrea Perdicchi | Dirigente Medico/Docente a contratto Sapienza | UOD Oftalmologia, Azienda Ospedaliera Universitaria Sant'Andre | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
Di pippo Mariachiara | Assegno di Ricerca Sapienza di tipo B categoria II MED 30- numero protocollo 210/2021 | UOD Oftalmologia, Università di Roma Sapienza | Altro personale aggregato Sapienza o esterni, titolari di borse di studio di ricerca |
Background/ Objective: Age-related macular degeneration (AMD) is the most common cause of irreversible vision loss in the elderly in developed countries. Quiescent macular neovascularization (MNV) is a relatively newly described entity in AMD. Optical coherence tomography angiography (OCTA) is the ideal non-invasive imaging method that can reveal MNV in eyes without signs of clinical activity defined as the absence of subretinal or intraretinal fluid. Quiescent MNV can remain inactive for variable periods of time. The factors that determine their awakening to active disease or the relationship with geographic atrophy are unknown.
This research proposes to evaluate choriocapillaris vascular density and choroidal vascularity index (CVI) in treatment naïve quiescent MNV using spectral domain optical coherence tomography (SDOCT) and OCTA. The primary objective is to evaluate correlations of these quantitative parameters in the possible conversion to exudative MNV or geographic atrophy over a period of 24 months. The secondary objective is to detect biomarkers that may predict conversion of quiescent disease to active forms of MNV.
Methods: Prospective study design to include patients with OCTA evidence of quiescent MNV with no signs of clinical activity and age matched healthy control subjects. Comprehensive ophthalmological examination will be carried out. SDOCT and OCTA will be performed and the size and morphology of quiescent MNV will be documented. Near infrared reflectance and fundus autofluorescence will be carried out for evaluation of the choroid and signs/progression of atrophy. Data for choriocapillaris vascular density will be obtained from OCTA incorporated software. CVI will be calculated using specific software in a method described by Sonoda et al. Statistical analysis will be based on correlations of choriocapillaris vascular density, choroidal vascularity index, and fundus autofluorescence data with changes in MNV size and activity status.